Evidence map›Paper›PMID 26449664›Full record

ArticleLeukemia2016

Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.

O A Haabeth, A Tveita, M Fauskanger, K Hennig, P O Hofgaard, B Bogen

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Cytotoxic CD4Frontiers in immunology · 2025
    Article
  2. Article
  3. CD4Nature cancer · 2023
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. CD4Cancer immunology, immunotherapy : CII · 2019
    Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

O A HaabethCentre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
A TveitaCentre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
M FauskangerCentre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
K HennigCentre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
P O HofgaardKG Jebsen Centre for Influenza Vaccine Research, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
B BogenCentre for Immune Regulation, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsCD4-Positive T-LymphocytesHumansImmunoglobulin IdiotypesImmunotherapyMiceMice, Inbred BALB CMultiple MyelomaImmunoglobulin Idiotypes

Identifiers

PMID26449664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.